Chlorphenamine Maleate

Content
Download/Print

Definition

Chlorphenamine maleate is a first-generation antihistamine used in both human and veterinary medicine. It belongs to the chemical group of alkylamines and acts as a competitive antagonist at H1 receptors. In human medicine, it is contained in numerous cold and allergy preparations (e.g., Grippostad), while in veterinary medicine, it is primarily used to treat allergic reactions and itching. The substance is characterized by its anti-allergic, antiemetic, and sedative effects. Unlike newer antihistamines, chlorphenamine maleate crosses the blood-brain barrier, which explains its central nervous system effects. Improper use or overdose can lead to serious symptoms of poisoning in dogs and cats, with cats being particularly sensitive due to their specific metabolic pathways.

The most important facts at a glance

Chlorphenamine maleate poisonings in dogs and cats usually result from accidental overdose or accidental ingestion of human or veterinary medicines. The substance acts as an antihistamine and also has anticholinergic and sedative properties. The toxic dose in dogs is about 9 mg/kg, while cats can develop serious symptoms at even lower doses. Clinically, poisoning manifests through a wide range of symptoms, including neurological disorders (sedation to convulsions), gastrointestinal complaints (vomiting, diarrhea), and kidney dysfunction. The diagnosis is based on medical history, clinical picture, and laboratory tests. Therapy is symptomatic and includes decontamination, fluid therapy, forced diuresis, and supportive measures depending on the clinical presentation. With adequate treatment, the prognosis is favorable, and follow-up care focusing on kidney function is recommended. Preventively, pet owners should be educated about the safe storage of medications and the risks of self-medicating their pets.

Causes, development and progression

Chlorphenamine interferes with the body’s immune responses. It reduces the increased permeability of small blood vessels that occurs during infections and triggers muscle spasms in the lungs. The result is a decongestant effect on the mucous membranes of the respiratory tract. Furthermore, chlorphenamine has depressant (sedative) properties.
Chlorphenamine maleate is also approved for use in veterinary medicine. It is used in both dogs and cats to treat itching (allergic dermatitis).

Poisoning with chlorphenamine maleate in pets primarily arises from three scenarios:

  1. accidental overdose during veterinary treatment,
  2. unintentional administration of human medications by the pet owner, and
  3. unintended ingestion of such medications by the animal itself.

The toxic dose in dogs for oral ingestion is approximately 9 mg of chlorphenamine maleate per kilogram of body weight. In cats, the toxic threshold is lower, and doses as low as 4–6 mg/kg can lead to severe intoxication. This increased sensitivity in cats is due to their limited ability to metabolize certain medications, which is related to a lack of specific glucuronidation enzymes in the liver. Young, old, or chronically ill animals are particularly at risk, as are breeds with known drug sensitivity such as Collies or Australian Shepherds, which are often carriers of the MDR1 genetic defect.

Mechanism of action

In small animals, symptoms of intoxication with chlorphenamine maleate appear after about 10 hours.
The primary concern is damage to the kidneys with corresponding effects on the internal environment. Chlorphenamine maleate has a depressive effect on the nervous system and can lead to changes in the blood count.

Supplements

The pathophysiological mechanism of poisoning by chlorphenamine maleate in dogs and cats is based on an overdose of the active ingredient, which, as a first-generation antihistamine, has both peripheral and central effects.

1. Blockade of H1-histamine Receptors

Chlorphenamine acts primary as a competitive antagonist at H1 receptors. In the event of an overdose, the excessive blockade of these receptors leads to:

  • CNS depression (sedation, somnolence)
  • In higher doses or particularly in cats, also CNS stimulation (restlessness, tremors, convulsions)

2. Central effects via the blood-brain barrier

Since chlorphenamine is lipophilic, it easily crosses the blood-brain barrier. This explains the central nervous system effects such as:

  • Ataxia
  • altered consciousness
  • States of agitation or seizures during overstimulation

3. Anticholinergic Effects

Chlorphenamine also possesses anticholinergic properties by inhibiting muscarinic receptors, which can cause the following symptoms:

  • dry mouth (xerostomia)
  • Tachycardia
  • Urinary retention
  • mydriasis (pupil dilation)
  • Hyperthermia due to reduced sweat and heat regulation (primarily relevant in dogs)

4. Gastrointestinal effects

Irritation of the gastrointestinal tract or central effect on the vomiting center can lead to:

  • Vomiting
  • Diarrhea
  • anorexia

Symptoms of intoxication

Dogs in particular are sensitive to chlorphenamine maleate.
The toxic dose in dogs for oral ingestion is 9 mg maleic acid/kg body weight.
Initial symptoms are:

  • Sedation
  • Loss of appetite
  • Vomiting
  • Diarrhea
  • Thirst
  • Acidosis
  • Increase in metabolic waste products in the blood (urea, creatinine)
  • Apathy
  • Anemia
  • Decrease in white blood cells (agranulocytosis), decrease in platelets (thrombocytopenia).

Severe intoxications are characterized by

  • Agitation
  • Gait disorders (ataxia)
  • Tremor
  • Seizures.

In the final stage, there is

  • Cardiovascular collapse
  • Coma
  • Respiratory paralysis.

The clinical signs of chlorphenamine maleate poisoning typically manifest within 10 hours of ingestion and affect multiple organ systems. Initially, central nervous system symptoms such as sedation predominate, which can paradoxically turn into states of agitation, as well as coordination disorders (ataxia) and tremors. In cases of severe poisoning, convulsions can occur. Gastrointestinal disorders manifest as loss of appetite, vomiting, and diarrhea. Another characteristic is an impairment of kidney function, recognizable by increased thirst (polydipsia) and increased urination (polyuria), followed by an increase in nitrogenous substances in the blood (azotemia). Hematological changes include anemia, leukopenia, and thrombocytopenia. In advanced stages, cardiovascular complications such as tachycardia, arrhythmias, and hypotension can occur. If left untreated, there is a risk of cardiovascular collapse with coma and respiratory paralysis. In cats, hyperthermia and pronounced mydriasis can also be observed, while dogs more frequently react with hypersalivation and bradycardia.

Diagnosis

The diagnosis of chlorphenamine maleate poisoning is based on the medical history, clinical symptomatology, and laboratory findings. It is crucial to obtain a thorough history, especially regarding possible drug exposure. The clinical examination focuses on neurological, cardiovascular, and renal parameters. Laboratory diagnostics including a complete blood count, clinical chemistry tests with special attention to kidney values (urea, creatinine), as well as electrolytes and acid-base status are indicated. A urinalysis can provide evidence of renal involvement. Direct toxicological detection of chlorphenamine maleate in blood or urine using high-performance liquid chromatography (HPLC) or mass spectrometry is possible, but is rarely available in practice and is usually not timely enough for acute treatment decisions. Differential diagnosis must consider other intoxications (mainly with anticholinergics, amphetamines, or metaldehyde), metabolic disorders, and primary neurological diseases.

Therapeutic principles

For decontamination, accelerated excretion via the urine (forced diuresis) is aimed for.
There is no antidote.
The therapy is symptomatic.
Treatment is based on the predominant symptoms and disorders present.
Fluid loss (dehydration) resulting from vomiting is compensated for by infusions. At the same time, it is possible to compensate for acidosis by administering sodium bicarbonate.
Agents that suppress the vomiting center (antiemetics) and anticonvulsants are used as needed.
Furthermore, stabilization of vital functions such as circulation and respiration is necessary.
In the event of seizures, appropriate medications are used to control them.

Supplements

Treatment of chlorphenamine maleate poisoning is symptomatic, as no specific antidote exists. In cases of recent ingestion (< 2 hours), decontamination by inducing vomiting with apomorphine (dog: 0.02-0.04 mg/kg i.v.) or xylazine (cat: 0.44 mg/kg i.m.) may be considered, provided there are no contraindications. Alternatively, gastric lavage under general anesthesia may be considered. The administration of activated charcoal (1–4 g/kg p.o.) binds toxin still present in the gastrointestinal tract. Intensive care with fluid therapy to correct dehydration and electrolyte imbalances, as well as forced diuresis to accelerate the renal elimination of the toxin, is central. In cases of metabolic acidosis, the administration of sodium bicarbonate is indicated. Convulsions are treated with diazepam (0.5-2.0 mg/kg i.v.) or phenobarbital (2–4 mg/kg i.v.). Antiemetics such as maropitant (1 mg/kg s.c.) can be used for persistent vomiting. In cases of cardiovascular instability, infusions with colloidal solutions and possibly catecholamines may be necessary. Close monitoring of vital parameters, hydration status, and laboratory values is essential. In cases of severe renal failure, hemodialysis may be considered.

Prognosis & follow-up care

The prognosis is very good.

The prognosis for chlorphenamine maleate poisoning is generally favorable with early detection and adequate therapy. Crucial prognostic factors include the dose ingested, the time elapsed until the start of therapy, and the presence of pre-existing conditions. Animals with pre-existing kidney or liver diseases have an increased risk of complications. Most patients recover completely within 24–48 hours, with neurological symptoms often being the last to subside. In follow-up care, regular monitoring of kidney function over several weeks is recommended, as subclinical kidney damage may persist. For this purpose, blood tests to determine urea and creatinine levels as well as urine tests should be performed. In severe cases of poisoning, neurological deficits may remain, requiring long-term rehabilitation. The pet owner should be offered detailed advice on avoiding future drug exposure, including instructions on the safe storage of human medicines.

Research outlook

Current research in the field of chlorphenamine maleate poisoning in small animals focuses on several aspects: firstly, species-specific differences in pharmacodynamics and kinetics are being studied more closely to better understand the varying sensitivity of dogs and cats. Molecular biological studies analyze the genetic basis of drug intolerances, focusing on other potential genetic predispositions in addition to the known MDR1 genetic defect. In the field of diagnostics, new rapid testing methods are being developed to enable the quick identification of antihistamine poisoning in practice. Therapeutically, work is being done on improved decontamination protocols, including novel adsorbents with higher binding capacity and selectivity than conventional activated charcoal. In addition, innovative hemodialysis procedures are being evaluated to allow for more efficient elimination of toxins. Finally, research is concerned with the development of safer antihistamines for veterinary use that have a lower potential for toxicity even in the event of accidental overdose.

Frequently asked questions (FAQs)

  1. Which human medications contain chlorphenamine maleate and are dangerous for my pet?
    Chlorphenamine maleate is contained in many over-the-counter cold and allergy remedies, including Grippostad, Wick MediNait, and various antihistamine preparations. All of these products can lead to poisoning in pets and should not be administered without veterinary instruction.
  2. How quickly do poisoning symptoms appear after ingesting chlorphenamine maleate?
    The first symptoms can appear as early as 1–2 hours, typically the full poisoning picture develops within 10 hours of ingestion.
  3. Is my cat more sensitive to chlorphenamine maleate than my dog?
    Yes, cats are generally more sensitive to many medications, including chlorphenamine maleate, due to their limited ability to glucuronidate in the liver.
  4. Can I help my pet at home if I suspect poisoning?
    If poisoning is suspected, you should seek veterinary help immediately. Do not attempt to induce vomiting yourself or use home remedies, as this can worsen the situation.
  5. Are there long-term damages after recovering from chlorphenamine maleate poisoning?
    With timely treatment, most animals recover completely. In severe cases, however, permanent kidney damage or neurological deficits may remain.
  6. Which dog breeds are particularly at risk for drug poisoning?
    Dogs with the MDR1 genetic defect, such as Collies, Australian Shepherds, Shelties, and related breeds, are particularly sensitive to many medications, potentially including antihistamines.
  7. Can chlorphenamine maleate be safely administered to my pet at the correct dosage?
    Yes, at the correct dosage prescribed by a veterinarian, chlorphenamine maleate can be safely used to treat allergic reactions.
  8. How can I prevent my pet from being poisoned by medication?
    Store all medications in locked cabinets, do not administer human medications without veterinary instruction, and pay attention to the exact dosage of prescribed medications.

Literature

  • https://www.vetpharm.uzh.ch/clinitox/toxdb/KLT_026.htm
  • Wismer T. Toxicology of Antihistamines. Veterinary Clinics of North America: Small Animal Practice. 2018;48(6):1087-1096.
  • Fitzgerald KT, Bronstein AC. Antihistamine Toxicosis. In: Small Animal Toxicology. 3rd ed. St. Louis: Elsevier; 2020:563-577.
  • Gwaltney-Brant SM. Antihistamines. In: Peterson ME, Talcott PA, editors. Small Animal Toxicology. 4th ed. Philadelphia: Elsevier; 2022:489-498.
  • Court MH. Feline drug metabolism and disposition: pharmacokinetic evidence for species differences and molecular mechanisms. Veterinary Clinics of North America: Small Animal Practice. 2021;51(6):1185-1206.
  • Mealey KL, Fidel J. P-glycoprotein mediated drug interactions in animals and humans with cancer. Journal of Veterinary Internal Medicine. 2019;33(6):2-10.
  • Löwe G, Löwe O. Poisonings in Dogs and Cats – A Veterinary Guide. 2nd Edition. Kreuztal: Kynos-Verlag. 2021; 208 p.